CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 258 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $2,027,384 | +564.7% | 36,113 | +619.2% | 0.05% | +278.6% |
Q2 2022 | $305,000 | -76.9% | 5,021 | -53.7% | 0.01% | -88.4% |
Q1 2021 | $1,323,000 | +196.0% | 10,855 | +78.3% | 0.12% | +290.3% |
Q2 2020 | $447,000 | -77.7% | 6,088 | -87.1% | 0.03% | -78.6% |
Q1 2020 | $2,004,000 | -38.9% | 47,255 | -12.3% | 0.14% | -25.3% |
Q4 2019 | $3,282,000 | +672.2% | 53,893 | +420.0% | 0.19% | +424.3% |
Q3 2019 | $425,000 | -8.8% | 10,364 | +4.7% | 0.04% | -11.9% |
Q2 2019 | $466,000 | -70.1% | 9,901 | -81.9% | 0.04% | -56.7% |
Q4 2018 | $1,559,000 | +523.6% | 54,558 | +868.5% | 0.10% | +410.5% |
Q3 2018 | $250,000 | -52.1% | 5,633 | -50.6% | 0.02% | -47.2% |
Q1 2018 | $522,000 | +21.7% | 11,410 | -37.6% | 0.04% | -23.4% |
Q4 2017 | $429,000 | – | 18,285 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |